Discrepancies between the in vitro and in vivo effects of HE may reflect the presence and recycling ability of hemopexin following its delivery of HE to hepatocytes, which supports the prevalence of unbound hemopexin and a persistent HE scavenging activity in vivo [59, 60]. This evidence concerns the gene HPX and hereditary elliptocytosis.